Log in Free sign up

Cybin (CYBN) News and press releases

News

From Benzinga Pro

GH Research, Numinus Wellness Among Top Psychedelic Movers Of Today

Cannabis, Markets, Movers

GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 3.03% at $0.85

10 Psychedelics CEOs To Pay Attention To In 2022

Cannabis, News, Penny Stocks, Psychedelics, Small Cap, Exclusives, Markets

By Javier Hasse and Aaron Bry. 2020 and 2021 were defining years for the burgeoning psychedelics industry. In 2021 alone, more than $730 million were invested into various psychedelic companies, both private and public.

Cybin's Psilocybin Analog CYB003 Gets FDA Clearance For Trial To Potentially Treat Major Depressive Disorder

Biotech, Cannabis, News, Psychedelics, Legal, Markets, General

Psychedelic biopharma company Cybin Inc. (NEO: CYBN) has received FDA Investigational New Drug Application (IND) approval for a Phase 1/2a clinical trial evaluating its proprietary CYB003 for treating major depressive disorder (MDD).

Allied, Revive Therapeutics Among Top Psychedelic Movers Of Today

Cannabis, Markets, Movers

GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 3.12% at $0.82

Cybin Receives FDA IND Clearance For Its Phase 1/2a Clinical Trial Evaluating CYB003 For The Potential Treatment Of Major Depressive Disorder

Biotech, News, FDA, General

Cybin Inc. (NEO:CYBN) (NYSE:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that it has received a “may proceed

Allied, Revive Therapeutics Among Top Psychedelic Movers Of Today

Cannabis, Markets, Movers

GAINERS: Allied (OTC:ALID) shares closed up 29.44% at $0.56

Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today

Cannabis, Markets, Movers

GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 6.63% at $0.71

Psychedelic Stock Gainers And Losers From June 22, 2022

Cannabis, Markets, Movers

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 4.17% at $3.50

Cybin Closes Fiscal Year 2022, Reports Financial Results And Major Achievements

Cannabis, Earnings, News, Penny Stocks, Psychedelics, Management, Markets

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), a biopharma company focused on progressing “psychedelics to therapeutics” through proprietary drug discovery platforms announced its financial and business results ended March 31, 2022.

Revive Therapeutics, Numinus Wellness Among Top Psychedelic Movers Of Today

Cannabis, Markets, Movers

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 7.43% at $0.31

Psychedelic Stock Gainers And Losers From June 17, 2022

Cannabis, Markets, Movers

GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 5.69% at $0.67

Psychedelic Stock Gainers And Losers From June 16, 2022

Cannabis, Markets, Movers

GAINERS: GH Research (NASDAQ:GHRS) shares closed up 3.08% at $10.05 LOSERS:

Psychedelic Stock Gainers And Losers From June 15, 2022

Cannabis, Markets, Movers

GAINERS: Cybin (AMEX:CYBN) shares closed up 9.11% at $0.62

Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill

Cannabis, News, Penny Stocks, Psychedelics, Markets

Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider.

Psychedelic Stock Gainers And Losers From June 14, 2022

Cannabis, Markets, Movers

GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 9.90% at $9.44

ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today

Cannabis, Markets, Movers

GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 1.06% at $0.81 LOSERS:

Cybin Moves Forward With Phase 1/2a Clinical Trial For Treatment Of Major Depressive Disorder

Cannabis, News, Psychedelics, FDA, Markets

Psychedelic Stock Gainers And Losers From June 10, 2022

Cannabis, Markets, Movers

GAINERS: Cybin (AMEX:CYBN) shares closed up 6.16% at $0.67

Elon Musk Says Psychedelics Should Be Seriously Considered For Therapeutic Uses, Leading Chorus Of Celeb Support

Cannabis, News, Penny Stocks, Psychedelics, Markets

Elon Musk, the Tesla multi-billionaire investor and owner of the largest portion of Twitter (NYSE: TWTR) shares has been discus

Small Pharma, Cybin Among Top Psychedelic Movers Of Today

Cannabis, Markets, Movers

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 12.55% at $0.13

Press releases

From Benzinga Pro

Cybin Announces Additional Adelia Milestone Achievement

Cybin Inc. (NEO:CYBN) (NYSE:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a

Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder

-- Marks the first novel psilocybin analog to enter clinical development -- -- Patient recruitment to commence immediately -- -- Pharmacokinetic and safety data readout expected in Q4 2022 -- Cybin Inc. (NEO:CYBN)

Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights

- Company reiterates key pipeline and strategic milestones for 2022 – Cybin Inc. (NEO:CYBN) (NYSE:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM",

World's Richest Man Says Psychedelics Could Make a Real Difference in Mental Health

Small Cap, Opinion, Press Releases

FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, June 15, 2022 /PRNewswire/ -- Elon Musk believes that psychedelics and other plant-based drugs are better than pharma meds in treating a number of

Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

-- First-in-human Phase 1/2a trial evaluating the proprietary deuterated psilocybin analog CYB003 expected to begin in mid-2022 -- Cybin Inc. (NEO:CYBN) (NYSE:CYBN) (Cybin or the "Company"), a biopharmaceutical company

Cybin Announces Additional Adelia Milestone Achievements

Cybin Inc. (NEO:CYBN) (NYSE:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a

Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program

Cybin Inc. (NEO:CYBN) (NYSE:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™", today announced the team of 28 esteemed faculty and advisors who

Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy

Cybin Inc. (NEO:CYBN) (NYSE:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™", is pleased to announce the publication of a peer-reviewed article

Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder

-- CYB003 is the first psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder -- Cybin Inc. (NEO:CYBN) (NYSE:CYBN) (Cybin or the Company), a biopharmaceutical company

Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022

- In-person investor meetings taking place on May 18 and 19 in New York City - Cybin Inc. (NEO:CYBN) (NYSE:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to

American Billionaire Entrepreneurs Bet Millions on Psychedelics

Small Cap, Opinion, Press Releases

FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, May 10, 2022 /PRNewswire/ -- Billionaire Bob Parsons, the founder of GoDaddy, believes psychedelics can heal trauma. The Marine infantryman says LSD

Cybin Announces CYB003 Poster to be Presented at the 'From Research to Reality' Global Summit on Psychedelic-Assisted Therapies and Medicine

Cybin Inc. (NEO:CYBN) (NYSE:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", today announced that an abstract highlighting preclinical data for its

Oregon to Become the First State to Legally Roll Out Psilocybin

Small Cap, Opinion, Press Releases

FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK , April 28, 2022 /PRNewswire/ -- Oregon is set to become the first US state to market legal psilocybin, the psychoactive substance found in magic

Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022

Cybin Inc. (NEO:CYBN) (NYSE:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™" is pleased to announce that Doug Drysdale, Cybin's Chief Executive

Roth Capital Reveals Top Psychedelic Picks in New Industry Report

Small Cap, Opinion, Press Releases

FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, April 21, 2022 /PRNewswire/ -- Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report from Roth

Why Psychedelics Could Soon Replace Antidepressants

Small Cap, Opinion, Press Releases

FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, April 13, 2022 /PRNewswire/ -- Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults each year,

Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules

Cybin Inc. (NEO:CYBN) (NYSE:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™", today announced that the World Intellectual Property Organization

Cybin Announces Additional Adelia Milestone Achievement

Cybin Inc. (NEO:CYBN) (NYSE:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™", is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

Cybin Inc. (NEO:CYBN) (NYSE:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", today announced that the first study visit has been conducted in a